Elimination therapy for the endemic malarias

Current Infectious Disease Reports

Volumn 14, Issue 3, 2012, Pages 227-237

  Baird, J Kevin ^a,b  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

G6PD deficiency; Gametocytocidal; Malaria; Primaquine; Radical cure; Relapse

Indexed keywords

ANTIMALARIAL AGENT; PRIMAQUINE; TAFENOQUINE;

ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; ASYMPTOMATIC DISEASE; CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE CARRIER; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ENDEMIC DISEASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH HAZARD; HEMOLYSIS; HUMAN; INFECTION CONTROL; LOW DRUG DOSE; MALARIA; MALARIA FALCIPARUM; MIXED INFECTION; OPTIMAL DRUG DOSE; PARASITE CONTROL; PHENOTYPE; PLASMODIUM VIVAX MALARIA; RISK FACTOR; SCREENING TEST; SINGLE DRUG DOSE; TRAVEL; TREATMENT PLANNING;

EID: 84865624424     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-012-0250-z     Document Type: Article

References (64)

1. Coatney GR, Collins WE, Warren M, The CPG, Malarias P. United States Government Printing Office. DC: Washington; 1971. p. 366.
2. The Medical Letter. Drugs for parasitic infections. Treatment Guidelines from the Medical Letter. 2010;8(suppl):e1-20.
3. World Health Organization. Guidelines for the Treatment of Malaria (2nd Ed.). 2010. Geneva. 194pp.
4. Arguin PM, Mali S. Malaria. Chapter 3 in: The Yellow Book; CDC Health Information for International Travel 2012 (Brunette GW, ed). Oxford University Press. 640pp.
5. Baird JK. "Tropical Health and Sustainability", in Robert Meyers (ed.) Encyclopedia of Sustainability Science and Technology, 2012.In press.
6. Baird JK. Eliminating malaria -All of them. Lancet. 2010;376:1883-5.
7. Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: Neglected and not benign. AmJTrop Med Hyg. 2008;52:1040-5.
8. Baird JK. Neglect of Plasmodium vivax malaria. Trends Parasitol. 2007;23:533-9. (Pubitemid 350026468)
9. Kochar DK, Das A, Kochar A, et al. Clinical features of children hospitalized with malaria -A study from Bikaner, northwest India. Am J Trop Med Hyg 83: 981-9.
10. Barcus MJ, Basri H, Picarema H, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian New Guinea. AmJTrop Med Hyg. 2007;77:984-91. (Pubitemid 351837852)
11. Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: A prospective study in Papua. Indonesia PLoS Med. 2008;5: E128.
12. Genton B, D'Acremont V, Rare L, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: A prospective cohort study from Papua New Guinea. PLoS Med. 2008;5:e127.
13. Andrade BB, Reis-Filho A, Souza-Neto SM, et al. Severe Plasmodium vivax malaria exhibits marked inflammatory imbalance. Malaria J 2010; 9: 13. A case series of severe vivax malaria offering compelling laboratory evidence of the parasite as the agent inciting severe disease.
14. Beutler E, Duparc S. G6PD Deficiency Working Group. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. AmJTrop Med Hyg. 2007;77:779-89. (Pubitemid 351844308)
15. Baird JK, Surjadjaja C. Consideration of ethics in primaquine therapy against malaria transmission. Trends Parasitol 2011; 27: 11-6. A review of the clinical problem presented by primaquine and G6PDd and of the weakness of available evidence supporting its use.
16. Muhlenberger N, Jelinek T, Gascon J, et al. Epidemiology and clinical features of vivax malaria imported to Europe: Sentinel surveillance data from TropNetEurop. Malaria J. 2004;3:5.
17. Mali S, Tan KR, Arquin PM. Malaria surveillance -United States, 2009. MMWR Surveill Summ 2011; 60: 1-15. A comprehensive epidemiological snapshot of malaria as it occurs in a nonendemic developed country in 1 year.
18. Smith AD, Bradley DJ, Smith V, et al. Imported malaria and high risk groups: Observational study using UK surveillance data 1987-2006. BMJ. 2008;337:a120.
19. Antiori S, Cigardi B, Galimberti L, et al. Diagnosis and therapy for hospitalized imported malaria in adults in Italy. J Trav Med. 2011;18:379-85.
20. Guedes S, Siikamaki H, Kantele A, Lyytikainen O. Imported malaria in Finland 1995-2008: An overview of surveillance, travel trends, and antimalarial drug sales. J Trav Med. 2010;17:400-4.
21. Nsagha DS, Nsagha SM, Shey CU, et al. Knowledge, attitudes and practices relating to malaria in a semi-urban area of Cameroon: Choices and sources of antimalarials, self-Treatment and resistance. East Afr J Public Health. 2011;8:98-102.
22. Littrell M, Gatakaa H, Phok S, et al. Case management of malaria in Cambodia: results from national anti-malarial outlet and household surveys. Malaria J 2011; 10: 328. Provides a glimpse at malaria treatment realities in one Southeast Asian nation targeted for relatively aggressive interventions against the threat of artemisinin-resistant falciparum malaria.
23. Ndo C, Menze-Djantio B, Antonio-Nkondjio C. Awareness, attitudes and prevention of malaria in the cities of Douala and Yaounde (Cameroon). Parasite Vectors. 2011;4:181.
24. Nyandigisi A, Memusi D, Mbithi A, et al. Malaria casemanagement following change of policy to universal parasitological diagnosis and targeted artemisinin-base combination therapy in Kenya. PLoS One 2011; 6: E24781. Provides a glimpse at malaria treatment realities in one African endemic nation.
25. Yeung S, Patouillard E, Allen H, Socheat D. Socially-marketed rapid diagnostic tests and ACT in the private sector: 10 years of experience in Cambodia. Malaria J. 2011;10:243.
26. Mazumdar S. Prevalence, risk factors and treatment seeking behavior for malaria: The results of a case study from the Terai region of West Bengal, India. Ann Trop Med Parasitol. 2011;105:197-208.
27. Shaikh BT, Haran D. Treating common illnesses among children under 5 years: A portrayal of health-seeking behaviours and practices in the northern areas of Pakistan. World Health Popul. 2011;12:24-34.
28. Downs WG, Harper PA, Lisansky ET. Malaria and other insectborne diseases in the South Pacific campaign. 1942-1945. II. Epidemiology of insect-borne diseases in Army troops. Am J Trop Med. 1947;27:69-89.
29. Douglas NM, Nosten F, Ashley EA, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 2011; 52: 612-20. A very large retrospective analysis of patients enrolled in clinical trials of therapies against falciparum malaria in Thailand. Findings remove doubt concerning high prevalence of hypnozoites of P. vivax even in relatively low transmission settings.
30. Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet. 1987;2:1052-5.
31. Karbwang J, Bangchang KN, Thanavibul A, et al. Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria. Lancet. 1992;340:1245-8.
32. Ashley EA, Krudsood S, Phaiphun I, et al. Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis. 2004;190:1773-82. (Pubitemid 39487822)
33. Smithius F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: An open-label randomized trial. Lancet Infect Dis 2010; 10: 673-81. A randomized trial of therapies for falciparum malaria showing high prevalence of hypnozoites of P. vivax among patients diagnosed with P. falciparum in a low transmission endemic setting.
34. Putaporntip C, Hongsrimuang T, Seethamachai S, et al. Differential prevalence of Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans in Thailand. J Inf Dis. 2009;199:1143-50.
35. Steenkeste N, Rogers WO, Okell L, et al. Sub-microscopic malaria cases and mixed infection in a remote area of high malaria endemicity in Rattanakiri province, Cambodia: Implication for malaria elimination. Malaria J 2010; 9: 108. Large study demonstrating problem of sub-patent and asymptomatic parasitemia in low transmission endemic setting.
36. Zakeri S, Kakar Q, Ghasemi F, et al. Detection of mixed Plasmodium falciparum & P. vivax infections by nested-PCR in Pakistan, Iran & Afghanistan. Indian J Med Res. 2010;132:31-5.
37. Mueller I, Widmer S, Michel D, et al. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malaria J 2009; 8: 41. A large cross-sectional study of people residing in a high transmission setting and exposed to 4 of the 5 species of plasmodia infecting humans naturally. A high throughput technology permitted relatively deep reach for absolute sensitivity of diagnosis and revealed a very high prevalence of mixed species infections (40%).
38. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22:13-36.
39. Hviid L. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Human Vaccines. 2010;6(1):84-9.
40. Harris I, Sharrock W, Bain LW, et al. A large proportion of asymptomatic Plasmodium infections with low and submicroscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: Challenges for malaria diagnostics in an elimination setting. Malaria J 2010; 9:254. A large crosssectional survey in a very low transmission setting demonstrating the reality of sub-patent and asymptomatic parasitemia being the dominant form of malaria (approx. 70% of infections detected by PCR were otherwise undetectable).
41. Roshanravan B, Karl E, Gilman RH, et al. Endemic malaria in the Peruvian Amazon region of Iquitos. AmJTropMed Hyg. 2003;69:45-52.
42. da Silva-Nunes M, Moreno M, Conn JE, et al. Amazonia malaria: Asymptomatic human reservoirs, diagnostic challenges, environmentally driven changes in mosquito vector populations and the mandate for sustainable control strategies. Acta Trop 2011; in press. Evidence showing the dominance of sub-patent and asymptomatic parasitemia in a low transmission Amazonian setting.
43. Sutcliffe CG, Kobayashi T, Hamapumbu H, et al. Changing individual-level risk factors for malaria with declining transmission in southern Zambia: A cross-sectional study. Malaria J. 2011;10:324.
44. Bin Mohanna MA, Bin Ghouth AS, Rajaa YA. Malaria signs and infection rate among asymptomatic schoolchildren in Hajr Valley, Yemen. East Mediterr Health J. 2007;13:35-40.
45. Incardona S, Vong S, Chiv L, et al. Large-scale malaria survey in Cambodia: Novel insights on species distribution and risk factors. Malaria J. 2007;6:37.
46. Kritsiriwuthinan K, Ngrenngarmlert W. Asymptomatic malaria infections among foreign migrant workers in Thailand. Asian Pac J Trop Med. 2011;4:560-3.
47. World Health Organization. Malaria rapid diagnostic test performance: Summary results of WHO product testing of malaria RDTs; rounds 1 and 2 (2008-2009). doi:10.2471/TDR.09.978-924-1599467.
48. World Health Organization. Consideration of mass drug administration for the containment of artemisinin resistant malaria in the greater Mekong subregion. Report of a Consensus Meeting, 27-28 September 2010, Geneva, Switzerland. 2011.
49. Epstein JE, Rao S, Williams F, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: An update. J Infect Dis. 2007;196:145-54. (Pubitemid 46982749)
50. Lyke KE, Laurens M, Adams M, et al. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One. 2010;5: E13490.
51. Wellems TE, Miller LH. Two worlds of malaria. New Engl J Med. 2003;349:1498-7.
52. Wells TNC, Burrows J, Baird JK. Targeting the hypnozoite reservoir of Plasmodium vivax: The hidden obstacle to malaria elimination. Trends Parasitol. 2010;26:145-51.
53. Leslie T, Mayan I, Mohammed N, et al. A randomized trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One 2008; 3: 2861. Randomized clinical trial of an 8-week regimen for treatment against relapse developed 50 years ago for safety in undiagnosed G6PDd patients. This is the first evaluation of its efficacy in an endemic zone, and the first since its development. This regimen may prove useful in elimination therapy.
54. Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol. 2003;19:115-20. (Pubitemid 36338074)
55. Alving AS, Arnold J, Hockwald RS, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955;46:301-6.
56. Dow GS, Gettayacamin M, Hansukjariya P, et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynmolgi-infected Rhesus monkeys (Macaca mulatta). Malaria J 2011; 10: 212. Evidence in this paper affirms the vitally important chemotherapeutic principle of synergy between 8-Aminoquinolines and blood schizonticides against relapse, despite those blood schizonticides having no apparent effect on relapse when given without primaquine.
57. WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull WHO. 1989;67:601-11.
58. Ziai M, Amirhakimi GH, Reinhold JG, et al. Malaria prophylaxis and treatment in G6PD deficiency. Clin Ped. 1967;6:242-3.
59. Alving AS, Johnson CF, Tarlov AR, et al.Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull WHO. 1960;22:621-31.
60. Pannacciulli I, Tizianello A, Ajmar F, Salvidio E. The course of experimentally induced hemolytic anemia in a primaquinesensitive Caucasian: A case study. Blood. 1965;25:92-5.
61. Clark TG, Fry AE, Auburn S, et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum Genet. 2009;17:1080-5.
62. Schmidt LH, Fradkin R, Vaughan D, Rasco J. Radical cure of infections with Plasmodium cynomolgi: A function of total 8-Aminoquinoline dose. AmJTrop Med Hyg. 1977;12:51-60.
63. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2003;37:1659-67.
64. Wilairatana P, Tangpukdee N, Kano S, Krudsood S. Primaquine administration after falciparum malaria treatment in malaria hypoendemic areas with high incidence of falciparum and vivax mixed infection: Pros and cons. Korean J Parasitol. 2010;48:175-7.